5-FU与DDP腹腔灌注治疗晚期卵巢癌的临床比较

目的观察5-FU持续小剂量灌注与DDP常规灌注的疗效。方法38个晚期卵巢癌病人随机分为2组,19例采用腹腔留置管,5-FU250mgd1～14,对照组采用单次穿刺法,DDP50mg/m^2,2组均配合使用等剂量的吉西他滨静脉化疗,每3周1疗程。结果试验组有效率84.2%,对照组有效率68.4%,试验组优于对照组,且毒副反应可耐受。结论5-FU持续小剂量腹腔灌注化疗可能有很好的应用前景,值得进一步探讨。     

胃癌术后导入营养的临床应用研究

目的：对胃癌手术治疗后的营养导入进行分析探讨。方法：将我院半年期间因胃癌行根治性胃大部切除或全胃切除术的患者136例，随机分为肠内营养组合对照组两组，通过研究胃癌术后全肠内营养对患者术后的体型状况及胃功能恢复情况的影响作用，有无腹泻、呕吐、恶心等并发症。结果：在研究过程中，两组人员无严重并发症。对照组比肠内营养组的消化道症状更加多见，经过合理导入营养指导后12个月，患者的消瘦率和消瘦程度都有明显的改善，生活质量明显提高，肠内营养组较明显。     

Celecoxib 在人癌裸鼠移植瘤抗癌与放射增敏的作用机制研究

 目的　探讨选择性环氧化酶-2 抑制剂celecoxib 抗癌及放射增敏作用的可能机制。方法　构建人宫颈癌裸鼠移植瘤模型,celecoxib 和/ 或移植瘤局部放射干预,检测移植瘤生长延缓、移植瘤组织中环氧化酶-2 与前列腺素E2 含量的变化,并分析此变化与移植瘤生长延缓的关系。结果　移植瘤最大径从8mm 生长至10mm 所需的时间,空白对照组为(4. 42 ±0. 78) d ,单纯放射组为(6. 25 ±0. 70) d ,celecoxib组为(7. 14 ±1. 06) d ,celecoxib + 放射联合组为(10. 62 ±2. 06) d ;Western Blot 显示4 组移植瘤组织中环氧化酶22 水平无明显差异;前列腺素E2 (pg/ 100mg) 含量分别为:空白对照组69. 07 ±5. 42 ,单纯放射组47. 4 ±15. 94 ,单纯celecoxib 组28. 62 ±4. 48 ,celecoxib + 放射联合组为43. 2 ±11. 73 ,与空白对照组比较差异均有显著性( P = 0. 009 、0. 005 、0. 026) ;但celecoxib + 放射联合组与单纯放射组的前列腺素E₂ 含量无显著差异( P = 0. 28) ;celecoxib 引起的移植瘤生长延缓与前列腺素E₂ 含量降低正相关( r = 0. 741) 。结论　Celecoxib及移植瘤局部放射均能延缓移植瘤生长,不影响环氧化酶-2量的表达,但均能引起前列腺素E₂ 含量的降低;celecoxib 引起的移植瘤生长延缓可能与环氧化酶-2 活性被抑制后前列腺素E₂ 含量的降低有关。     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

紫杉醇脂质体对胃癌细胞系BGC-823增殖和侵袭力的影响

[目的]探讨紫杉醇脂质体和紫杉醇对胃癌细胞系BGC-823增殖状况和侵袭能力影响。[方法]用紫杉醇脂质体和紫杉醇处理人胃癌BGC-823细胞，倒置显微镜下观察细胞形态变化，MTT绘制细胞生长曲线，TUNEL检测细胞凋亡，细胞划痕法和Transwell检测胃癌细胞的侵袭力。[结果]用紫杉醇脂质体和紫杉醇处理胃癌BGC-823细胞后，细胞的增殖能力和体外侵袭能力明显减弱，凋亡率增加，但两者之间相比无显著性差异（P〉0．051。[结论]紫杉醇脂质体具有和紫杉醇相似的抑制胃癌BGC-823细胞增殖和侵袭的能力。     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

中西医结合治疗多发性骨髓瘤31例

目的观察益肾健脾,活血解毒法联合化疗方案治疗多发性骨髓瘤的疗效。方法全部病例均采用联合化疗配合中药口服治疗,2个疗程以上评定疗效。结果治疗前后实验室检查结果对比除尿素氮外,血红蛋白,M蛋白,血钙,血沉,骨髓中浆细胞比例均见显著性差异(P<0.05)。结论中西医结合治疗多发性骨髓瘤能提高临床疗效。     

黄芪四物汤加减预防乳腺癌术后化疗白细胞减少的研究

目的 探讨乳腺癌术后进行化疗患者口服中药加减黄芪四物汤对化疗过程中白细胞减少症的临床预防效果.方法 收集我院2006年3月至2009年10月127例乳腺癌手术后患者,按患者自身情况及要求随机分为实验组与对照组.其中实验组71例化疗开始即口服加减黄芪四物汤;与对照组56例常规化疗患者.观察化疗过程中白细胞减少情况.并进行1-6个月随访,平均随访时间达4.8个月.结果 实验组因化疗引起的白细胞减少患者明显低于常规行化疗患者.结论 口服黄芪四物汤对乳腺癌化疗患者白细胞减少有明显的预防作用,临床应用效果佳.     

鞘注治疗小儿急性淋巴细胞白血病中枢神经浸润的研究

目的探讨鞘内注射化疗药物治疗小儿急性淋巴细胞白血病中枢神经系统浸润的临床效果。方法收集我院2007年1月至2009年12月,153例小儿急性淋巴细胞白血病中枢神经浸润患者,采用全身化疗联合应用阿糖胞苷（Ara-c）甲氨喋呤（MTX）,地塞米松（DXM）等药物鞘内注射进行治疗,并进行1～6个月的临床观察。结果经3～10次鞘内注射药物,临床症状明显改善,脑脊液恢复或接近正常。除1例死于肺部感染外,153例患儿无再次发生中枢神经浸润症状。结论全身化疗联合鞘内注射可有效防治小儿急性淋巴细胞白血病中枢神经浸润。